News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Simcere Pharmaceutical Group Raises $65 Million by Selling Its Boda Pharma Subsidiary



6/24/2013 12:52:26 PM

Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today!

by Richard Daverman, PhD

June 24, 2013 -- Simcere Pharma of Nanjing agreed to sell its 99.99% stake in Jilin Boda Pharma for 400 million RMB ($65 million). Simcere bought an initial 51% ownership of Boda in 2007 for $15 million. Both Boda and Simcere produce injectible edaravone drugs that act as neuroprotectives following a stroke. The Boda sale has taken place after Simcere’s Chairman offered $503 million to take Simcere private, and the $65 million in sale proceeds will render the take-private deal easier to finance. More details....

Stock Symbol: (NYSE: SCR)

Help employers find you! Check out all the jobs and post your resume.

Read at ChinaBio Today


comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES